179 related articles for article (PubMed ID: 32568366)
1. Association Between Common Variants in RBFOX1, an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease.
Raghavan NS; Dumitrescu L; Mormino E; Mahoney ER; Lee AJ; Gao Y; Bilgel M; Goldstein D; Harrison T; Engelman CD; Saykin AJ; Whelan CD; Liu JZ; Jagust W; Albert M; Johnson SC; Yang HS; Johnson K; Aisen P; Resnick SM; Sperling R; De Jager PL; Schneider J; Bennett DA; Schrag M; Vardarajan B; Hohman TJ; Mayeux R;
JAMA Neurol; 2020 Oct; 77(10):1288-1298. PubMed ID: 32568366
[TBL] [Abstract][Full Text] [Related]
2. Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease.
Young CB; Winer JR; Younes K; Cody KA; Betthauser TJ; Johnson SC; Schultz A; Sperling RA; Greicius MD; Cobos I; Poston KL; Mormino EC;
JAMA Neurol; 2022 Jun; 79(6):592-603. PubMed ID: 35435938
[TBL] [Abstract][Full Text] [Related]
3. Associations of the Top 20 Alzheimer Disease Risk Variants With Brain Amyloidosis.
Apostolova LG; Risacher SL; Duran T; Stage EC; Goukasian N; West JD; Do TM; Grotts J; Wilhalme H; Nho K; Phillips M; Elashoff D; Saykin AJ;
JAMA Neurol; 2018 Mar; 75(3):328-341. PubMed ID: 29340569
[TBL] [Abstract][Full Text] [Related]
4. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
5. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.
Jansen WJ; Janssen O; Tijms BM; Vos SJB; Ossenkoppele R; Visser PJ; ; Aarsland D; Alcolea D; Altomare D; von Arnim C; Baiardi S; Baldeiras I; Barthel H; Bateman RJ; Van Berckel B; Binette AP; Blennow K; Boada M; Boecker H; Bottlaender M; den Braber A; Brooks DJ; Van Buchem MA; Camus V; Carill JM; Cerman J; Chen K; Chételat G; Chipi E; Cohen AD; Daniels A; Delarue M; Didic M; Drzezga A; Dubois B; Eckerström M; Ekblad LL; Engelborghs S; Epelbaum S; Fagan AM; Fan Y; Fladby T; Fleisher AS; Van der Flier WM; Förster S; Fortea J; Frederiksen KS; Freund-Levi Y; Frings L; Frisoni GB; Fröhlich L; Gabryelewicz T; Gertz HJ; Gill KD; Gkatzima O; Gómez-Tortosa E; Grimmer T; Guedj E; Habeck CG; Hampel H; Handels R; Hansson O; Hausner L; Hellwig S; Heneka MT; Herukka SK; Hildebrandt H; Hodges J; Hort J; Huang CC; Iriondo AJ; Itoh Y; Ivanoiu A; Jagust WJ; Jessen F; Johannsen P; Johnson KA; Kandimalla R; Kapaki EN; Kern S; Kilander L; Klimkowicz-Mrowiec A; Klunk WE; Koglin N; Kornhuber J; Kramberger MG; Kuo HC; Van Laere K; Landau SM; Landeau B; Lee DY; de Leon M; Leyton CE; Lin KJ; Lleó A; Löwenmark M; Madsen K; Maier W; Marcusson J; Marquié M; Martinez-Lage P; Maserejian N; Mattsson N; de Mendonça A; Meyer PT; Miller BL; Minatani S; Mintun MA; Mok VCT; Molinuevo JL; Morbelli SD; Morris JC; Mroczko B; Na DL; Newberg A; Nobili F; Nordberg A; Olde Rikkert MGM; de Oliveira CR; Olivieri P; Orellana A; Paraskevas G; Parchi P; Pardini M; Parnetti L; Peters O; Poirier J; Popp J; Prabhakar S; Rabinovici GD; Ramakers IH; Rami L; Reiman EM; Rinne JO; Rodrigue KM; Rodríguez-Rodriguez E; Roe CM; Rosa-Neto P; Rosen HJ; Rot U; Rowe CC; Rüther E; Ruiz A; Sabri O; Sakhardande J; Sánchez-Juan P; Sando SB; Santana I; Sarazin M; Scheltens P; Schröder J; Selnes P; Seo SW; Silva D; Skoog I; Snyder PJ; Soininen H; Sollberger M; Sperling RA; Spiru L; Stern Y; Stomrud E; Takeda A; Teichmann M; Teunissen CE; Thompson LI; Tomassen J; Tsolaki M; Vandenberghe R; Verbeek MM; Verhey FRJ; Villemagne V; Villeneuve S; Vogelgsang J; Waldemar G; Wallin A; Wallin ÅK; Wiltfang J; Wolk DA; Yen TC; Zboch M; Zetterberg H
JAMA Neurol; 2022 Mar; 79(3):228-243. PubMed ID: 35099509
[TBL] [Abstract][Full Text] [Related]
6. Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimer's pathophysiology.
Ramanan VK; Lesnick TG; Przybelski SA; Heckman MG; Knopman DS; Graff-Radford J; Lowe VJ; Machulda MM; Mielke MM; Jack CR; Petersen RC; Ross OA; Vemuri P;
Acta Neuropathol Commun; 2021 Mar; 9(1):48. PubMed ID: 33757599
[TBL] [Abstract][Full Text] [Related]
7. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
8. Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals.
Sperling RA; Donohue MC; Raman R; Sun CK; Yaari R; Holdridge K; Siemers E; Johnson KA; Aisen PS;
JAMA Neurol; 2020 Jun; 77(6):735-745. PubMed ID: 32250387
[TBL] [Abstract][Full Text] [Related]
9. Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis.
Knopman DS; Jack CR; Wiste HJ; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Roberts RO; Boeve BF; Petersen RC
JAMA Neurol; 2013 Aug; 70(8):1030-8. PubMed ID: 23797806
[TBL] [Abstract][Full Text] [Related]
10. Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment.
Strikwerda-Brown C; Hobbs DA; Gonneaud J; St-Onge F; Binette AP; Ozlen H; Provost K; Soucy JP; Buckley RF; Benzinger TLS; Morris JC; Villemagne VL; Doré V; Sperling RA; Johnson KA; Rowe CC; Gordon BA; Poirier J; Breitner JCS; Villeneuve S;
JAMA Neurol; 2022 Oct; 79(10):975-985. PubMed ID: 35907254
[TBL] [Abstract][Full Text] [Related]
11. Association of Cortical β-Amyloid Protein in the Absence of Insoluble Deposits With Alzheimer Disease.
Yu L; Petyuk VA; Tasaki S; Boyle PA; Gaiteri C; Schneider JA; De Jager PL; Bennett DA
JAMA Neurol; 2019 Jul; 76(7):818-826. PubMed ID: 31009033
[TBL] [Abstract][Full Text] [Related]
12. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.
Bilgel M; An Y; Helphrey J; Elkins W; Gomez G; Wong DF; Davatzikos C; Ferrucci L; Resnick SM
Brain; 2018 Aug; 141(8):2475-2485. PubMed ID: 29901697
[TBL] [Abstract][Full Text] [Related]
13. Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β.
Therriault J; Benedet AL; Pascoal TA; Mathotaarachchi S; Chamoun M; Savard M; Thomas E; Kang MS; Lussier F; Tissot C; Parsons M; Qureshi MNI; Vitali P; Massarweh G; Soucy JP; Rej S; Saha-Chaudhuri P; Gauthier S; Rosa-Neto P
JAMA Neurol; 2020 Apr; 77(4):470-479. PubMed ID: 31860000
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide interaction study of brain beta-amyloid burden and cognitive impairment in Alzheimer's disease.
Roostaei T; Nazeri A; Felsky D; De Jager PL; Schneider JA; Pollock BG; Bennett DA; Voineskos AN;
Mol Psychiatry; 2017 Feb; 22(2):287-295. PubMed ID: 27021820
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
[TBL] [Abstract][Full Text] [Related]
16. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.
Mattsson-Carlgren N; Salvadó G; Ashton NJ; Tideman P; Stomrud E; Zetterberg H; Ossenkoppele R; Betthauser TJ; Cody KA; Jonaitis EM; Langhough R; Palmqvist S; Blennow K; Janelidze S; Johnson SC; Hansson O
JAMA Neurol; 2023 Apr; 80(4):360-369. PubMed ID: 36745413
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.
Gordon BA; Blazey T; Su Y; Fagan AM; Holtzman DM; Morris JC; Benzinger TL
JAMA Neurol; 2016 Oct; 73(10):1192-1200. PubMed ID: 27548756
[TBL] [Abstract][Full Text] [Related]
18. Genetic susceptibility for Alzheimer disease neuritic plaque pathology.
Shulman JM; Chen K; Keenan BT; Chibnik LB; Fleisher A; Thiyyagura P; Roontiva A; McCabe C; Patsopoulos NA; Corneveaux JJ; Yu L; Huentelman MJ; Evans DA; Schneider JA; Reiman EM; De Jager PL; Bennett DA
JAMA Neurol; 2013 Sep; 70(9):1150-7. PubMed ID: 23836404
[TBL] [Abstract][Full Text] [Related]
19. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
[TBL] [Abstract][Full Text] [Related]
20. Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study.
Jack CR; Wiste HJ; Weigand SD; Rocca WA; Knopman DS; Mielke MM; Lowe VJ; Senjem ML; Gunter JL; Preboske GM; Pankratz VS; Vemuri P; Petersen RC
Lancet Neurol; 2014 Oct; 13(10):997-1005. PubMed ID: 25201514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
